Daniel is a pharma industry and life sciences strategy consultant who has worked across the pharmaceutical, life science tools, data analytics, and private equity industries. His experiences include leading portfolio strategy for the immuno-oncology franchise at Pfizer and partnering with clients across the life sciences industry to answer key business questions primarily focused on corporate and business development strategy. Daniel is particularly interested in how tightening budgets, increased competition and emerging technologies are pressuring the pharma industry to find a quicker and more efficient way to develop drugs. Daniel holds a Ph.D. in Biology from M.I.T. and an AB from UC Berkeley in Molecular and Cellular Biology with a focus on genetics.